THOMAS R SCIASCIA, M.D.
Neurology at Oliver Rd, Belmont, MA
License number
Massachusetts 47700
Category
Neurology
Type
Neurology
Address
Address
108 Oliver Rd, Belmont, MA 02478
Phone
(617) 484-2267
Personal information
See more information about THOMAS R SCIASCIA at radaris.comName
Address
Phone
108 Oliver Rd, Belmont, MA 02478
Belmont, MA
108 Oliver Rd, Belmont, MA 02478
100 Oliver Rd, Belmont, MA 02478
88 Ellery St, Cambridge, MA 02138
Professional information
Dr. Thomas R Sciascia, Belmont MA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Thomas R Sciascia MD
108 Oliver Rd, Belmont 02478
(617) 484-2267 (Phone)
108 Oliver Rd, Belmont 02478
(617) 484-2267 (Phone)
Certifications:
Neurology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1979
University Of Michigan Hospitals
Boston Medical Center
Columbia University / College of Physicians And Surgeons
Graduated: 1979
University Of Michigan Hospitals
Boston Medical Center
Sustained Release Formulation Of Nalbuphine
US Patent:
2013016, Jun 27, 2013
Filed:
Feb 21, 2013
Appl. No.:
13/773136
Inventors:
PHILIP A. GOLIBER - LASNE, BE
ANTHONY E. CARPANZANO - NEW MILFORD CT, US
THOMAS SCIASCIA - BELMONT MA, US
DONALD DIEHL, II - NEW FAIRFIELD CT, US
BRIAN VOGLER - NORTH WHITE PLAINS NY, US
DAVID VERBEL - NEW YORK NY, US
STANLEY AU - BETHESDA MD, US
ANTHONY E. CARPANZANO - NEW MILFORD CT, US
THOMAS SCIASCIA - BELMONT MA, US
DONALD DIEHL, II - NEW FAIRFIELD CT, US
BRIAN VOGLER - NORTH WHITE PLAINS NY, US
DAVID VERBEL - NEW YORK NY, US
STANLEY AU - BETHESDA MD, US
Assignee:
PENWEST PHARMACEUTICALS CO. - CHADDS FORD PA
International Classification:
A61K 9/00
US Classification:
424400, 514282
Abstract:
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Sustained Release Formulations Of Nalbuphine
US Patent:
2009003, Jan 29, 2009
Filed:
May 23, 2008
Appl. No.:
12/154496
Inventors:
Anand R. Baichwal - Wappingers Falls NY, US
Philip A. Goliber - Lasne, BE
Anthony E. Carpanzano - New Milford CT, US
Thomas Sciascia - Belmont MA, US
Donald Diehl, II - New Fairfield CT, US
Brian Vogler - North White Plains NY, US
David Verbel - New York NY, US
Stanley Au - Bethesda MD, US
Philip A. Goliber - Lasne, BE
Anthony E. Carpanzano - New Milford CT, US
Thomas Sciascia - Belmont MA, US
Donald Diehl, II - New Fairfield CT, US
Brian Vogler - North White Plains NY, US
David Verbel - New York NY, US
Stanley Au - Bethesda MD, US
International Classification:
A61K 31/485, A61P 25/00
US Classification:
514282
Abstract:
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Sustained Release Torsemide Dosage Forms
US Patent:
2007019, Aug 23, 2007
Filed:
Dec 15, 2006
Appl. No.:
11/640083
Inventors:
Pradeep Sanghvi - Schererville IN, US
Sara Ketsela - Danbury CT, US
Thomas Sciascia - Belmont MA, US
Theodore Jaworski - Cary NC, US
Sara Ketsela - Danbury CT, US
Thomas Sciascia - Belmont MA, US
Theodore Jaworski - Cary NC, US
Assignee:
Penwest Pharmaceuticals Co. - Patterson NY
International Classification:
A61K 9/22, A61K 31/44
US Classification:
424468000, 514346000
Abstract:
Disclosed in certain embodiments is a sustained release oral dosage form comprising an effective amount of torsemide or a pharmaceutically acceptable salt thereof and a sustained release excipient, wherein the dosage form provides a mean sodium (Na) excretion and mean sodium (Na) excretion rate as disclosed herein.
Sustained Release Formulations Of Nalbuphine
US Patent:
2007004, Mar 1, 2007
Filed:
Aug 24, 2006
Appl. No.:
11/509347
Inventors:
Anand Baichwal - Wappingers Falls NY, US
Philip Goliber - Brookfield CT, US
Anthony Carpanzano - New Milford CT, US
Thomas Sciascia - Belmont MA, US
Donald Diehl - New Fairfield CT, US
Brian Vogler - White Plains NY, US
Philip Goliber - Brookfield CT, US
Anthony Carpanzano - New Milford CT, US
Thomas Sciascia - Belmont MA, US
Donald Diehl - New Fairfield CT, US
Brian Vogler - White Plains NY, US
Assignee:
Penwest Pharmaceuticals Co. - Wappingers NY
International Classification:
A61K 9/22, A61K 31/485
US Classification:
424468000, 514282000
Abstract:
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Sustained Release Torsemide Dosage Forms
US Patent:
2005016, Aug 4, 2005
Filed:
Dec 10, 2004
Appl. No.:
11/009800
Inventors:
Pradeep Sanghvi - Schererville IN, US
Sara Ketsela - Danbury CT, US
Thomas Sciascia - Belmont MA, US
Theodore Jaworski - Cary NC, US
Sara Ketsela - Danbury CT, US
Thomas Sciascia - Belmont MA, US
Theodore Jaworski - Cary NC, US
Assignee:
Penwest Pharmaceuticals Co. - Patterson NY
International Classification:
A61K009/22, A61K031/736
US Classification:
424468000, 514054000
Abstract:
A sustained release pharmaceutical formulation comprising torsemide or pharmaceutically acceptable salt thereof.
Methods For Treatment Of Pruritis
US Patent:
8637538, Jan 28, 2014
Filed:
Dec 14, 2012
Appl. No.:
13/715625
Inventors:
Thomas Sciascia - Belmont MA, US
Assignee:
Trevi Therapeutics, Inc. - New Haven CT
International Classification:
A01N 43/42
US Classification:
514279, 514282
Abstract:
The present invention relates to methods for treating uremic pruritus with anti-pruritic compositions.